Sangamo Therapeutics (SGMO) Reports Q2 Loss of $0.26
Sangamo Therapeutics (NASDAQ: SGMO) reported Q2 EPS of ($0.26), versus ($0.26) reported last year. Revenue for the quarter came in at $21.55 million, versus $17.55 million reported last year.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
